Leman (莱芒生物) was co-founded by Professor Tang Li's team at the Swiss Federal Institute of Technology in Lausanne (EPFL) and Jingtai Technology. It is an innovative tumor immunotherapy drug research and development company based on immune metabolic reprogramming (Meta 10) + cutting-edge artificial intelligence (AI), focusing on the research, development, production and commercialization of new tumor immunotherapy drugs. The core technology Meta 10 has shown great potential for curing solid tumors. The relevant results have been published in the top international academic journal Nature Immunology, and PCT patents have been applied for (entering 56 countries or regions, covering major economies in the world).